Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» obesity
obesity
Weight Loss From GLP-1 Drugs Not As Robust In Real-World Settings
Forbes
Wed, 10/2/24 - 11:20 am
weight loss
obesity
GLP-1 agonist
Ozempic
Wegovy
Novo Nordisk
Zepbound
Mounjaro
Eli Lilly
Kailera launches with $400M series A and clutch of Chinese obesity drugs
Fierce Biotech
Tue, 10/1/24 - 09:57 am
Kailera Therapuetics
China
funding
obesity
Cerevel Therapeutics
Rivus reveals data to back up muscle-sparing claims of phase 2 obesity drug
Fierce Biotech
Mon, 09/30/24 - 08:38 pm
Rivus Pharmaceuticals
obesity
heart failure
clinical trials
HU6
Roche targets more than $3 billion in annual obesity sales
Reuters
Mon, 09/30/24 - 10:09 am
Roche
Carmot Therapeutics
obesity
diabetes
BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials
Fierce Biotech
Wed, 09/25/24 - 11:48 am
BioAge Labs
IPO
obesity
biotech
Inside the GLP-1 'price war'
Beckers Hospital Review
Tue, 09/24/24 - 11:52 am
GLP-1 agonists
obesity
weight loss
Eli Lilly
Novo Nordisk
Ozempic
Wegovy
Zepbound
Mounjaro
drug pricing
Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand
Clinical Trials Arena
Tue, 09/24/24 - 11:51 am
Arrowhead Pharmaceuticals
clinical trials
ARO-INHBE
RNAi
obesity
New Zealand
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson’s candidate for $27M
Fierce Biotech
Mon, 09/23/24 - 11:33 am
Sanofi
Ventyx Biosciences
obesity
Parkinson's Disease
Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
Fierce Biotech
Fri, 09/20/24 - 11:30 am
Novo Nordisk
obesity
weight loss
clinical trials
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
Reuters
Thu, 09/19/24 - 09:16 pm
Novo Nordisk
Wegovy
obesity
EMA
Europe
heart failure with preserved ejection fraction
Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says
CNBC
Thu, 09/19/24 - 11:13 am
Novartis
Pharma CEOs
weight loss
obesity
Vas Narasimhan
Obesity pill race heats up as Novo, Roche and Terns share data
BioSpace
Tue, 09/17/24 - 11:22 am
obesity
Novo Nordisk
Roche
Terns Pharmaceuticals
amycretin
TERN-601
CT-996
clinical trials
‘The trajectory is encouraging.’ Roche hopes obesity drug will show 25% weight loss one day
Fierce Biotech
Wed, 09/11/24 - 11:15 pm
Roche
obesity
CT-388
Carmot Therapeutics
Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial
Fierce Biotech
Wed, 09/11/24 - 11:53 am
Novo Nordisk
obesity
clinical trials
amycretin
Study backs role of Novo Nordisk obesity drug in children
Pharmaphorum
Wed, 09/11/24 - 11:36 am
Novo Nordisk
pediatrics
obesity
clinical trials
Saxenda
Immunis receives FDA clearance for Phase II sarcopenic obesity therapy trial
Clinical Trials Arena
Wed, 09/11/24 - 11:22 am
Immunis
FDA
clinical trials
Immuna
obesity
sarcopenic obesity
Weight-loss market to see 16 new drugs by 2029, report estimates
Reuters
Tue, 09/10/24 - 04:29 pm
weight loss
obesity
Amgen
Pfizer
Roche
Novo Nordisk
Eli Lilly
Boehinger Ingelheim
Structure Therapeutics
Viking Therapeutics
Zealand Pharma
Altimmune
Terns Pharmaceuticals' oral obesity drug shows promise in early study, shares jump
Reuters
Mon, 09/9/24 - 11:29 am
Terns Pharmaceuticals
obesity
clinical trials
OrsoBio Announces Oversubscribed $67 Million Series B Financing to Accelerate Mitochondrial Protonophore Portfolio Targeting Obesity and Associated Disorders
Businesswire
Fri, 09/6/24 - 10:50 am
OrsoBio
obesity
funding
57 Million Eligible For GLP-1 Drug Coverage In U.S. And That’s Just Those Under 65
Forbes
Thu, 09/5/24 - 10:29 pm
obesity
GLP-1
Novo Nordisk
Eli Lilly
Ozempic
Wegovy
insurers
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »